GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

NexgenRx NXG.V · CAD

Financials · TSX Venture · 🇨🇦 Canada

Compare

0.67

—

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About NexgenRx

Its shares trade on TSX Venture under the ticker NXG.V. It has been listed since 14 September 2006. In the fiscal year to 31 December 2025, it reported revenue before interest expense of C$17.9m and net income of C$1.3m. At that date it held total assets of C$36.6m and shareholders' equity of C$7.6m.

NexgenRX, Inc. engages in the design, management, and administers, adjudicates and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans in Canada. The company is headquartered in Toronto, California. The company went IPO on 2006-09-14. The firm is engaged in the sale of its administration and health benefit claims adjudication services to organizations managing health benefit plans on behalf of plan sponsors, such as employers and associations, among others, and to the Canadian plan sponsors providing an Administrative Services Only (ASO) health benefit plan to their plan members. The health benefit claims include drug, dental, extended health and healthcare spending account claims. The firm sells its service on a fee-per-transaction basis, in addition to per member administration fees. The firm's Web-based product, theclaimsXchange.com, offers a platform, which allows various extended health providers to submit claims on behalf of their patients for benefits through a Web portal.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Financials
Industry
Insurance
Listed since
14 Sept 2006
Employees
20

Leadership

Pay as last reported

  • Mr. Thomas CorcoranIndependent Chairman of the Board, since 2004C$30,000
  • Mr. Ronald LoucksPresident, Chief Executive Officer, Director, since 2003C$313,342
  • Mr. Kelly EhlerChief Financial OfficerC$60,000
  • Mr. Andrew MunroeSenior Vice President - Pharma and Payor PartnersC$169,401
  • Ms. Linda BrennanDirector
  • Mr. Charles BurnsDirectorC$22,500
  • Mr. Randy McglynnIndependent DirectorC$20,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • NexgenRx Inc has several strengths that contribute to its success in the market.

Weaknesses

  • Despite its strengths, NexgenRx Inc also has several weaknesses that need to be addressed.

Opportunities

  • NexgenRx Inc can leverage the following opportunities to drive growth and expand its market reach.

Threats

  • NexgenRx Inc faces certain threats that may hinder its growth and profitability.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.